Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

BACKGROUND: Melanoma brain metastasis is associated with an extremely poor prognosis, with a median overall survival of 4–5 months. Since 2011, the overall survival of patients with stage IV melanoma has been significantly improved with the advent of new targeted therapies and checkpoint inhibitors....

Descripción completa

Detalles Bibliográficos
Autores principales: Vosoughi, Elham, Lee, Jee Min, Miller, James R., Nosrati, Mehdi, Minor, David R., Abendroth, Roy, Lee, John W., Andrews, Brian T., Leng, Lewis Z., Wu, Max, Leong, Stanley P., Kashani-Sabet, Mohammed, Kim, Kevin B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924486/
https://www.ncbi.nlm.nih.gov/pubmed/29703161
http://dx.doi.org/10.1186/s12885-018-4374-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924486/
https://www.ncbi.nlm.nih.gov/pubmed/29703161
http://dx.doi.org/10.1186/s12885-018-4374-x

Ejemplares similares